Stage 3 – mRNA Vaccine Formulation & Fill/Finish

MANUFACTURING FACILITY

2,500m² formulation and Fill/ Finish automation.

SKILLED WORKFORCE

Creation of 120 new and highly skilled, full time positions.

PRODUCTION CAPACITY

Production Plasmid DNA vaccines production capability of 1 million doses each month. Lipid Nanoparticles for 50 million mRNA vaccine doses each month. Fill/ finish capability to AU population scale.

TECHNOLOGY CAPABILITY

World-leading ‘GMP formulation and fill finish’ automation, state-of-the-art bioprocessing, chemical process technologies and proprietary manufacturing techniques.

JOBS CREATION

Over 2,500 Australian jobs for people in construction, manufacturing, specialist fields, bio-medical and consulting.

OPERATIONAL TIMEFRAME

Expected operationalisation within 6-months, after Stage 2 – estimated late-April 2023.